View Older Stories View More Recent Stories

May 30, 2019 07:30AM New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
May 30, 2019 07:30AM New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
May 23, 2019 09:06AM Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
May 20, 2019 07:30AM Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation
May 20, 2019 07:30AM Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation
May 15, 2019 06:02AM Biogen (BIIB) Reports Positive Recommendation for SPINRAZA (nusinersen) from NICE for Funding with U.K.'s National Health Service
May 14, 2019 07:02PM Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
May 14, 2019 07:02PM Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
May 10, 2019 08:40AM Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease
May 7, 2019 07:38AM Biogen (BIIB) Says Data at AAN Demonstrate its Leadership and Commitment to Innovation in MS
May 7, 2019 07:30AM Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
May 7, 2019 07:30AM Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
May 6, 2019 07:30AM Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)
May 6, 2019 07:30AM Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)
May 1, 2019 04:30PM Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
May 1, 2019 04:30PM Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
May 1, 2019 07:30AM Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
May 1, 2019 07:30AM Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
Apr 30, 2019 07:45AM Biogen (BIIB) Reports Data Publication in Neurology Showing that Treatment with SPINRAZA (nusinersen) Improved Motor Function, Provided Long-Term Benefit
Apr 30, 2019 07:33AM Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy
Apr 30, 2019 07:33AM Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy
Apr 29, 2019 07:34AM Biogen (BIIB) Announces Three New Nominees for Election to Board
Apr 29, 2019 07:30AM Biogen Announces Three New Nominees for Election to Board of Directors
Apr 29, 2019 07:30AM Biogen Announces Three New Nominees for Election to Board of Directors
Apr 12, 2019 07:31AM Biogen (BIIB) Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA
Apr 12, 2019 07:30AM Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
Apr 12, 2019 07:30AM Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
Mar 21, 2019 07:01AM Biogen (BIIB), Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in AD Due to Futility
Mar 21, 2019 07:00AM Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
Mar 21, 2019 07:00AM Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
Mar 19, 2019 08:30AM Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer
Mar 12, 2019 06:18AM Biogen (BIIB) Reports Agreement to Sell Biologics Manufacturing Site in Denmark to Fujifilm for Up to $890M
Mar 12, 2019 03:00AM Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm
Mar 11, 2019 11:00PM Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm
Mar 4, 2019 05:53AM Biogen (BIIB) to Acquire Nightstar Therapeutics (NITE) for $25.50/Sh in Deal Valued at Approx. $800M
Mar 4, 2019 02:00AM Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
Mar 4, 2019 02:00AM Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
Mar 1, 2019 08:18PM Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
Feb 28, 2019 07:39AM Biogen (BIIB) Expands Presence in China with Approval of SPINRAZA
Feb 28, 2019 07:30AM Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
Feb 28, 2019 07:30AM Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
Feb 25, 2019 07:37AM Alkermes (ALKS) and Biogen (BIIB) Announce FDA Acceptance of Diroximel Fumarate NDA for MS
Feb 25, 2019 07:30AM Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Feb 25, 2019 07:30AM Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Feb 25, 2019 07:30AM Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Feb 7, 2019 09:27AM Pre-Open Stock Movers 02/07: (IRBT) (LCI) (STI) Higher; (SLDB) (OSUR) (GRUB) Lower (more...)
Jan 4, 2019 07:32AM Biogen (BIIB) Reports Strategic Collaboration with Skyhawk Therapeutics to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Jan 4, 2019 07:31AM Biogen (BIIB) Reports Strategic Collaboration with C4 Therapeutics to Discover and Develop Potential New Treatments for Neurological Conditions
Jan 4, 2019 07:31AM Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Jan 4, 2019 07:30AM Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
View More Recent Stories View Older Stories